The FDA granted accelerated approval to sunvozertinib (Zegfrovy, Dizal [Jiangsu] Pharmaceutical) for adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion mutations, as detected by an FDA-approved test, whose disease has progressed on or after platinum-based chemotherapy.
The FDA also approved the Oncomine Dx Express Test (Life Technologies Corp.) as a companion diagnostic device to aid in detecting